In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.
Brain Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Computer Simulation
Glioblastoma
/ drug therapy
Humans
Inhibitory Concentration 50
Mebendazole
/ chemistry
Mitogen-Activated Protein Kinase 14
/ antagonists & inhibitors
Models, Molecular
Molecular Targeted Therapy
Protein Kinase Inhibitors
/ pharmacology
MAPK14
cancer
drug target prediction
glioblastoma
mebendazole
polypharmacology
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
30
05
2020
revised:
27
08
2020
accepted:
29
09
2020
pubmed:
7
10
2020
medline:
4
9
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already-approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to investigate the mechanism of action of mebendazole, an antihelminthic drug, currently repurposed in the treatment of brain tumors. First, we confirmed that mebendazole decreased the viability of glioblastoma cells in vitro (IC
Identifiants
pubmed: 33021050
doi: 10.1002/1878-0261.12810
pmc: PMC7718943
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Mebendazole
81G6I5V05I
Mitogen-Activated Protein Kinase 14
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3083-3099Informations de copyright
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
J Chem Inf Model. 2009 Jan;49(1):84-96
pubmed: 19125657
Mol Biosyst. 2009 Sep;5(9):1051-7
pubmed: 19668871
J Comput Aided Mol Des. 2013 Jan;27(1):15-29
pubmed: 23269578
Cancer Med. 2020 Jul;9(13):4676-4685
pubmed: 32400117
Oncotarget. 2017 Feb 21;8(8):12576-12595
pubmed: 28157711
Molecules. 2017 Aug 02;22(8):
pubmed: 28767069
Immunopharmacol Immunotoxicol. 2017 Aug;39(4):199-210
pubmed: 28472897
Nat Struct Biol. 2003 Sep;10(9):764-9
pubmed: 12897767
J Neurooncol. 2012 Aug;109(1):35-44
pubmed: 22528800
Neuro Oncol. 2011 Sep;13(9):974-82
pubmed: 21764822
J Neurooncol. 2018 Dec;140(3):529-538
pubmed: 30414098
Lancet Oncol. 2013 May;14(6):e239-48
pubmed: 23639324
Cancer Lett. 2018 Jan 1;412:118-130
pubmed: 29080749
Mol Cancer Ther. 2015 Jan;14(1):3-13
pubmed: 25376612
Cancer Lett. 2015 Mar 28;358(2):220-231
pubmed: 25542083
Br J Haematol. 2008 May;141(5):598-606
pubmed: 18397345
Mol Cancer Ther. 2014 Feb;13(2):364-74
pubmed: 24356814
Sci Rep. 2017 Jul 28;7(1):6812
pubmed: 28754988
Sci Rep. 2017 Jun 19;7(1):3820
pubmed: 28630414
Cancer Res. 2015 Oct 1;75(19):3997-4002
pubmed: 26377941
Mol Cancer Ther. 2002 Nov;1(13):1201-9
pubmed: 12479701
Cancer Chemother Pharmacol. 2008 Apr;61(5):809-17
pubmed: 17581752
Mol Cancer Res. 2008 Aug;6(8):1308-15
pubmed: 18667591
Int J Cancer. 2018 Sep 1;143(5):1176-1187
pubmed: 29582423
Nat Rev Clin Oncol. 2015 Dec;12(12):732-42
pubmed: 26483297
Vet Comp Oncol. 2017 Dec;15(4):1445-1454
pubmed: 28078780
Clin Cancer Res. 2016 Mar 1;22(5):1095-102
pubmed: 26581242
Nat Rev Clin Oncol. 2017 Jun;14(6):381-390
pubmed: 28290490
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
J Med Chem. 2007 Sep 6;50(18):4453-70
pubmed: 17676829
Sci Adv. 2016 Apr 01;2(4):e1501290
pubmed: 27757426
ChemMedChem. 2018 Jun 20;13(12):1160-1164
pubmed: 29633584
J Med Chem. 2012 Aug 9;55(15):6832-48
pubmed: 22780961
Mol Cancer. 2018 Feb 19;17(1):48
pubmed: 29455673
Autophagy. 2012 Jul 1;8(7):1098-112
pubmed: 22647487
Front Oncol. 2017 Nov 14;7:273
pubmed: 29184849
Protein Expr Purif. 2004 Sep;37(1):154-61
pubmed: 15294293
Invest New Drugs. 2018 Apr;36(2):323-331
pubmed: 28852916
Oncotarget. 2016 Oct 18;7(42):68571-68584
pubmed: 27612418
Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954
pubmed: 27899562
BMC Bioinformatics. 2011 Dec 20;12:484
pubmed: 22185703
Clin Cancer Res. 2002 Sep;8(9):2963-9
pubmed: 12231542
Oncotarget. 2018 Jul 20;9(56):30805-30813
pubmed: 30112108
Mol Cancer Ther. 2007 Apr;6(4):1212-22
pubmed: 17406030
Genome Med. 2011 Nov 28;3(11):77
pubmed: 22122801
Neuro Oncol. 2015 Apr;17(4):545-54
pubmed: 25253417
Mol Med. 2017 Apr;23:50-56
pubmed: 28386621
Neuroscience. 2017 May 20;351:84-95
pubmed: 28341197
Pharmacol Res. 2020 Feb;152:104609
pubmed: 31862477
Chem Biol Drug Des. 2019 Jul;94(1):1390-1401
pubmed: 30916462
Nat Commun. 2015 Oct 27;6:8620
pubmed: 26503418
J Neurosurg. 2004 Jun;100(6):1060-5
pubmed: 15200121
Br J Cancer. 2013 Jun 25;108(12):2485-94
pubmed: 23695022
EMBO Mol Med. 2013 Nov;5(11):1759-74
pubmed: 24115572
Expert Rev Clin Pharmacol. 2013 Jan;6(1):41-7
pubmed: 23272792
J Med Chem. 2017 Oct 26;60(20):8552-8564
pubmed: 28945083